



Worsening Heart Failure: Role of Vericiguat in Current Clinical Practice

Dr.Praneeth Gorantla

Dr.B.Vinod Kumar

SriRamachandra Institute of Higher Education and Research, India.

ABSTRACT :

INTRODUCTION : **Vericiguat** is a novel oral Soluble Guanylate Cyclase (sGC) *Stimulator* . On stimulation it leads to a signaling cascade which converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). cGMP levels increase & protein kinase G (PKG) is inactivated, resulting in a decrease of intracellular free Ca^{+} causes vascular smooth muscle cell relaxation.

AIM AND OBJECTIVES :

1. Study the efficacy , tolerance and compliance of Vericiguat in patients presented with worsening heart failure being treated with guideline directed medical therapy in south Indian population .
2. 30 day Hospitalisation events .
3. Comment on Challenges faced in achieving the target dose of Vericiguat & maintenance of guideline directed medical therapy in target population

METHODS : From hospital records of Sri Ramachandra medical centre , department of cardiology , We collected medical records and details of patients admitted with symptoms of heart failure in last one year who were started on T Vericiguat and analysed the clinical profile of these patients .

These patients were later followed up for current dose of Vericiguat , tolerance of drugs and improvement in symptoms of heart failure , Hospitalization events , adverse events and mortality .

RESULTS : 35 patients were followed up over a mean duration of 156 days ,out of which 2 patients discontinued treatment or lost followup . Of the remaining 33 patients ,1 patient discontinued due to adverse event (hypotension).

Results of remaining 32 patients are as follows -

Cv death / first hospitalisation due to heart failure	N =7 (21%)
30 day hospitalisations	N = 6 (18%)
All cause mortality	N = 9 (28%)
Symptom controll with no readmission	N = 23 (71.8%)

Keywords:Vericiguat , href , Victoria Trial, Mortality , Hospitalisation , Anaemia.